北京中医药大学学报2025，Vol.48Issue(9)：1197-1202,6.DOI:10.3969/j.issn.1006-2157.2025.09.003
从"瘤络瘀阻"探析癌旁围刺在肿瘤治疗中的应用
Application of peri-tumoral acupuncture in tumor treatment from the perspective of"tumor collateral stasis"
摘要
Abstract
Based on"collateral disease,"this paper proposes the theory of"tumor collateral stasis"as the core pathogenesis of tumors,taking tumor localization as the research object,tumor blood vessels as the structural basis,and tumor microenvironment as the biological basis."Tumor collateral stasis"is a generalization of tumor pathogenesis and a pathological product of the tumor.With the aging of the population,malignant tumors in older individuals have become a common problem worldwide.Older patients with malignant tumors are often frail,with declined organ physiological function and several comorbidities.Most of them find it difficult to tolerate the standard treatment of western medicine and require individualized diagnosis and treatment plans.Recently,traditional Chinese medicine has been explored and practiced in the treatment of older patients with malignant tumors and has achieved good therapeutic effects.Peri-tumoral acupuncture can dredge meridians,activate collaterals,warm and promote yang qi,strengthen local defenses,and promote blood circulation to resolve stasis.Under the guidance of the"tumor collateral stasis"theory,we applied peri-tumoral acupuncture to treat cancer pain,low anterior resection syndrome in rectal cancer,tumor suppression,recurrence prevention,and organ preservation,achieving excellent results.This study provides novel insights for clinical tumor treatment,especially in the treatment of older patients with malignant tumors.关键词
瘤络瘀阻/肿瘤微环境/癌旁围刺/肿瘤治疗/临床应用Key words
tumor collateral stasis/tumor microenvironment/peri-tumoral acupuncture/tumor treatment/clinical application分类
医药卫生引用本文复制引用
陈悦,黄金昶..从"瘤络瘀阻"探析癌旁围刺在肿瘤治疗中的应用[J].北京中医药大学学报,2025,48(9):1197-1202,6.基金项目
北京中医药大学揭榜挂帅项目(No.2022-JYB-JBZR-042) （No.2022-JYB-JBZR-042）
北京中医药大学新教师启动基金项目(No.2023-JYB-XJSJJ-053) （No.2023-JYB-XJSJJ-053）
